The relationship between the Tirzepatida, and the thyroid raises concern, especially for the sake of a warning to the information in the official Mounjaro studies carried out on mice and found an increase in tumors of the C-cells of thyroid function during exposure to Tirzepatida.
This may seem daunting at first glance, but there is a fundamental difference between what happened to the animals, and that it has already been demonstrated in humans.
At the moment, that is well-established that the Tirzepatida to cause cancer, medullary thyroid function in humans. Clinical trials and meta-analyses have also demonstrated no statistically significant increase in cancer of the thyroid, although follow-up is still relatively short, to delete thoroughly with a risk of rare, long-term.
On the side of caution, the drug is contra-indicated for individuals with a personal history or a family member of a medullary carcinoma of the thyroid, and for those with the syndrome of multiple endocrine neoplasia type 2, it is known as the 2.
This does not mean that it is any disease of the thyroid is to prevent the treatment.
Hypothyroidism, Hashimoto's thyroiditis, and thyroid nodules are different and must be evaluated individually.
In this article, you are going to understand what it really means to alert involving Tirzepatida, and the thyroidwhat people should not use the drug, and what the signs are worth investigating.
- Important: this content is purely informative and does not replace evaluation by a doctor. People with a history of cancer of the thyroid, nodules, or endocrine disorders should be to inform you of these terms to the trader prior to the start of the treatment.
There is a warning about your thyroid?
Before a drug is approved for use in humans, different studies are conducted in animals to investigate the possible toxic effects.
In the studies of the carcinogenicity of the Tirzepatida, male and female rats showed an increase dependent on the dose and duration of treatment on the incidence of cancer of C-cells of the thyroid.
Have been observed in pituitary adenomas and carcinomas.
The C-cells are specialized cells that produce calcitonin, and they are related to the development of medullary carcinoma of the thyroid.
It was just such an outcome, which has led to the creation of a statement of the specific information from the drug.
The key point is that the label says it is not known whether this effect was observed in mice are relevant to humans.
This means that the Tirzepatida causes cancer of the thyroid?
It is not right to say that.
Studies in animals have raised a risk, but it has not established a causal relationship between the Tirzepatida, and medullary carcinoma of the thyroid in humans.
The instructions in the brazilian states explicitly that it is not known if the medicine causes tumors in the C-cells, including cancer, spinal cord, and in human beings.
The prescribing information in north america, brings the same result.
So, to say that “Mounjaro causes cancer of the thyroid into a warning, caution should be exercised in a statement that the current evidence does not allow you to do that.
At the same time, it would be wrong to say that the risk is definitely not zero.
Tumors of the thyroid are relatively rare, cancer can take many years to develop. This makes it necessary to continue with the data from the long-term safety.
The studies in humans show?
A meta-analysis published in the year 2025, we evaluated the clinical trials of a Tirzepatida carried out during the period between 26 and 72 weeks.
The researchers found no increased overall risk of cancer or on specific types of cancer in participants treated with Tirzepatida.
Although there have been increases in calcitonin, in certain doses, and the trials included, did not show a clear sign of the cancer, the thyroid is associated with the treatment.
Another meta-analysis published in 2026 was evaluated based therapies in the incretinas, including drugs acting on the GLP-1) and Tirzepatida.
Have been analyzed and 15 randomized controlled trials involving more than 84 thousand people.
Took place on 28 cases of cancer of the thyroid in the treatment groups, and 15th among the controls.
The statistical analysis did not find a significant association between any of these therapies, and in cancer of the thyroid.
However, the authors graded the certainty of evidence as very low due to the small number of events, and the limited time of follow-up.
This is the scenario of current scientific: there is not an increase in clear, but we still don't have the decades of follow-up.
What is medullary carcinoma of the thyroid?
The medullary carcinoma of the thyroid, or CMT, is a relatively rare form of cancer that arises from cells in the C.
It is different from cancer of papilliferous, which is the most common type of cancer of the thyroid.
This distinction is very important when we're discussing Tirzepatida, and the thyroid.
In the alert, the bulls are specifically bound to the C-cells, and medullary carcinoma.
It does not mean that all of the different types of cancer, thyroid pose the same hazard, or are from the same source.
All cases of medullary carcinoma happens sporadically.
The other part of it is related to the heritable genetic damage, especially mutations in the gene for RET.
Who should not use Tirzepatida because of this risk?
The instructions for the brazilian contraindica Mounjaro for people with:
- the personal history of medullary carcinoma of the thyroid;
- a family history of medullary carcinoma of the thyroid;
- multiple endocrine neoplasia type 2, or 2.
This doesn't apply to just be for a family member with any problems in the thyroid.
For example, a parent with an underactive thyroid does not automatically mean a family history of medullary carcinoma.
In the same way, a family member, who did the surgery for a lump to be benign do not fit necessarily in this contraindication.
The exact type of the disease, does it make a difference.
What it is NOT 2?
OR 2 is multiple endocrine neoplasia type 2.
It is an inherited syndrome is related mainly to changes in the gene and the RET.
The affected individuals present a higher risk of medullary carcinoma of the thyroid, and may also develop other tumors of the endocrine, such as pheochromocytoma.
There are many different sub-types of the disorder.
Because of the close relationship between OR 2) and medullary carcinoma, those with such a condition should use Tirzepatida according to the official version of the drug.
Who has the hypothyroidism you can use Tirzepatida?
You have hypothyroidism by itself, does not appear as a contra-indication in the official data.
Hypothyroidism means that the gland produces insufficient amount of thyroid hormones.
The causes include Hashimoto's thyroiditis, and treatment of prior thyroid surgery, and other conditions.
This is quite different from that of carcinoma in bone marrow.
Thus, a person who uses levothyroxine should not automatically lead to the conclusion that you can't use Tirzepatida.
The decision depends on the clinical picture completely.
And who's thyroiditis?
The Hashimoto's thyroiditis is an autoimmune disease.
The immune system produces antibodies that attack in progress of the thyroid, which can lead to hypothyroidism.
Hashimoto's not cancer, spinal cord, and do not appear as a contra-indication-specific Mounjaro.
Who's thyroiditis should continue with the TSH, free T4, and the rest of the exams set by the endocrinologist.
While a significant loss of weight, and it may also be necessary to re-evaluate the doses of the medication such as levothyroxine.
This is because the needs of the hormone may change due to weight, absorption, and other medical conditions.
Tirzepatida can cause hypothyroidism?
Hypothyroidism is not one of the major adverse effects of established medicine.
The current evidence does not allow us to say that the Tirzepatida may cause hypothyroidism in people without the disease in advance.
There are recent studies evaluating possible changes in the tireoidianas during the treatment period, but the data are still limited, and does not justify the claim of a causal relationship.
For people who already have the disease, the thyroid may need a follow-up of normal hormones, irrespective of the use of the Tirzepatida.
Anyone who has a lump in the thyroid function can I use?
To have a node does not automatically mean that the person will not be able to use Tirzepatida.
Thyroid nodules are very common and most are benign.
However, the label directs people to the nodes identified on physical examination or on imaging studies to be evaluated properly.
This is especially true when the sentence has not yet been investigated.
Depending on the type, the endocrinologist may ask for the ultrasound, laboratory tests, and, in some cases, the puncture-aspiration fine needle.
The evaluation of the following criteria are used to the lumps in the thyroid in general.
A lump means cancer.
No.
This is a confusion of the ordinary.
A large portion of the nodes that are found in the ultrassonografias is not at risk.
The doctors will evaluate the features, such as:
- size;
- format;
- banks;
- composition
- the presence of calcifications;
- the relationship between the height and the breadth of it;
- the appearance of the lymph nodes that are close together.
The combination of these features will help you decide if the sentence needs only to follow-up, or if it merits further investigation.
In the presence of a nodule that does not mean that the Tirzepatida may have contributed to the problem.
It is necessary to do ultrasound of the thyroid-before using Mounjaro?
There is a recommendation to perform ultrasonic testing in the routine of all the people, only because of the will of the drug.
Your own label tells you that the value of the ultrasound, the thyroid is routine for the early detection of medullary carcinoma during treatment, it is up in the air.
This is because the nodules are very common.
If all of us come to the ultrasonic repeated, with no clinically indicated, may be found in the numerous nodules that are small that they will never cause problems, leading to further tests, and procedures are not necessary.
An ultrasound should only be used when there is a clinical indication.
Do I need to measure calcitonin prior to the treatment.
Also, there is no universal recommendation for a dose of calcitonin from the routine of all for the people.
Calcitonin is a hormone that is produced by the cells of C.
Values are significantly high, it may appear in patients with medullary carcinoma, but there are many other situations that can alter the test.
For that reason, the package insert of the brazilian and the united states argue that the usefulness of routine monitoring of calcitonin for the early detection of MTC is uncertain.
The instructions for the brazilian it tests all its aspects, can generate procedures are not required.
If calcitonin is required, and it is significantly high, the output should be checked out by a professional, be responsible.
Who has the TSH high, you need to stop Tirzepatida?
There is no such a rule.
The TSH high, it may indicate hypothyroidism or you need to adjust to the hormone replacement.
It is not the risk of cancer, spinal cord that is mentioned in the warning is the Mounjaro.
A person with a change in the TSH is required to investigate the cause, and to adjust treatment when needed.
It is not recommended to stop a Tirzepatida only on the basis of a change, isolated, without an evaluation by a doctor.
Weight loss can you change the dose of levothyroxine?
You can.
People who lose weight can significantly show the changes in the requirements for hormone replacement.
In addition to this, the Tirzepatida it slows down the gastric emptying time, and it could influence the absorption of a drug administered by mouth.
This is not to say that all of the people that they have to change the levothyroxine.
But those who use hormone replacement, you must keep track of the TSH and free T4 in accordance with the opinion of the endocrinologist, especially for the large changes in weight.
The dose should never be adjusted only on the basis of the symptoms.
What are the symptoms of thyroid issues deserve attention.
The label guides a search, evaluation, look for signs that it may appear in the tumors of thyroid, including the following:
- the appearance of a mass or lump in the neck:
- trouble swallowing;
- shortness of breath, with no explanation;
- hoarseness, and persistent.
These symptoms do not necessarily mean you have cancer.
Infections, diseases, benign, and a number of other conditions that can cause similar changes.
The importance is that you should not ignore persistent symptoms.
Hoarseness mean in cancer?
Most of the time, it's not.
Hoarseness may occur for a respiratory infection, acid reflux, strength, voice, and many other factors.
The warning refers primarily to a hoarseness, persistent, and with no explanation, especially when it is accompanied by a mass in the neck, or trouble swallowing.
In this scenario, it is appropriate to seek a medical evaluation.
A lump in the neck, needs to be investigated?
Yes.
Any kind of persistent neck deserves a trial, regardless of the use of the Tirzepatida.
You can look in the region and decide if it is necessary to perform an ultrasound, or other screening.
Once again, the goal is not to create fear.
The majority of thyroid nodules are benign.
But only for a proper assessment to be able to determine which ones are in need of follow-up.
There is a difference between a cancer, papilliferous, and spinal cord?
Yes, and this distinction is of fundamental importance.
The papilliferous carcinoma is a cancer, the most frequent form of thyroid and grows from the follicle cells.
Already in the medullary carcinoma arises from cells in the C.
The warning is related to the Tirzepatida is based on the treatment of C-cells was observed in the mice.
Therefore, it is not right to take the warning about cancer, spinal cord, and apply it automatically to any type of cancer in the thyroid.
Anyone who has ever had another type of cancer, you need to discuss your history, especially with the specialist.
Anyone who has had cancer, papilliferous you can use Tirzepatida?
This does not automatically match the contra-indication-specific is described in the instructions for use, which refers to cancer, spinal cord, and NOT the 2.
In the meantime, anyone with a history of cancer of the thyroid function should report to your doctor exactly which one it was the type level.
Diagnosis, previous treatment, the current situation of the disease, and follow-up cancer patients or endocrinological need to be taken into account.
It is not appropriate to make a decision by the general term “cancer of the thyroid”.
A family history of hypothyroidism, is when?
No.
The a when it refers specifically to the personal history or family member medullary carcinoma of the thyroid.
You have a mother, a father, a brother, or a grandmother with hypothyroidism-or Hashimoto's not the same thing.
This difference is known to cause a lot of confusion, because the label use to the expression, “a family history of cancer of the thyroid, but the type that you specify in the medullary carcinoma.
If the family history is not known, it may be worthwhile to find out which one is the exact diagnosis.
If you don't know, what is cancer, my family was?
If this is the case, tell your doctor.
If a close relative has had cancer of the thyroid, and no one knows which one has been diagnosed, you can consider researching the history, prior to the start of the drug.
At times, the reports of the surgery, pathological or medical records, the former are able to assist you.
This is especially important when there are multiple family members are affected, or the suspicion of an inherited syndrome.
Why not take the exams in an excess of security?
In health care, most exams do not always mean better security.
Ultrassonografias are able to identify smaller nodules are very common in the population.
Many of them never cause any problems.
Research unchecked, can lead to;
- repeated examinations;
- stamps are unnecessary;
- anxiety
- surgery may not be necessary.
It is for this reason that the proper information is official Tirzepatida, and the thyroid they say that the value of the monitor routinely, calcitonin, or to perform an ultrasound in all patients, it is up in the air.
The follow-up should be guided by individual risk.
What do we know about the long-term?
It continues to be one of the most important limitations of the evidence to support it.
All randomized clinical trials are usually included with the participants during the month or in the next few years.
A rare cancer can take a long time to come.
At the same time, a meta-analysis of tens of thousands of participants, you may not be able to discard altogether of a small increase in risk.
The meta-analysis by 2026, with more than 84 thousand participants, no association was found a statistically significant difference between the therapies that are based on the incretinas, and cancer of the thyroid.
However, the researchers emphasize that it is the rarity of the event and the time of the follow-up to reduce the certainty of the conclusion.
This is justification for maintaining appropriate safety and long term studies.
I need to be afraid to use Tirzepatida for the sake of the thyroid?
The warning must be taken seriously, but it should not be taken out of context.
For people without a personal history or family member with cancer, spinal cord, and do NOT (2), the human data are available so far have not demonstrated a clear increase in cancer of the thyroid.
On the other hand, there is no follow-up, which is long enough to declare that the risk is zero.
The correct way is to assess the benefits and risks of the individual.
For some people with obesity, type 2 diabetes, and the metabolic benefits of the treatment can be quite substantial.
For those with a contra-indication-specific, it should be used for different strategy.
Frequently asked questions
Tirzepatida causes cancer of the thyroid?
It is not established that it causes cancer of the thyroid in humans. Tumors of the C-cells were observed in the rats, and I still don't know what's the relevance of this finding to human beings.
Who has the hypothyroidism you can use Mounjaro?
Hypothyroidism, by itself, does not appear as a contra-indication-specific. The appreciation of which depends on the history, clinical examination.
Those who have Hashimoto can you use it?
Hashimoto's also not in the same condition as medullary carcinoma. The follow-up of thyroid disease should continue as normal.
Those who have the nodes you can use the Tirzepatida?
A node does not automatically amount to when, but it must be rated accordingly.
I need to make the cleaner before they start?
There is no universal recommendation for ultrasound-guided routine, solely for the sake of the treatment.
Do I need to measure calcitonin?
The package insert states that the value of routine monitoring of calcitonin, is up in the air. The test can be used when there is a clinical indication.
Anyone who has had cancer, spinal cord, can use it?
No. The personal history of cancer, spinal cord, is among the contraindications are described in the official data.
And if my father, and my mother had cancer, spinal cord?
Family history is also a contraindication.
Conclusion
The relationship between the Tirzepatida, and the thyroid it needs to be explained much more precisely than would normally appear on the social network.
The Tirzepatida has caused tumors in the C-cells in the rat during long-term studies.
However, it has yet to be established, which may cause medullary carcinoma of the thyroid in humans.
A Meta-analysis of the available studies did not find statistically significant increase in cancer in the thyroid, but the number of events is small and the follow-up also does not allow you to delete thoroughly with a risk of rare, long-term.
Be sure to Mounjaro is contra-indicated for individuals with a personal history or a family member of a medullary carcinoma of the thyroid, and in patients with an OR of 2.
This does not mean that the hypothyroidism, Hashimoto's or any of the inputs will automatically be contraindicated.
Also, there is a recommendation to make calcitonin, and an ultrasound again and again in all of the people just because they have started to Tirzepatida.
The main point is to get to know the history correctly.
Those who have thyroid disease you must tell the professional what is the exact diagnosis, and those with a mass in the neck, difficulty in swallowing, shortness of breath, unexplained, or hoarseness, persistent, you should seek an evaluation.
In this way, the discussion on the Tirzepatida, and the thyroid it may be based on the evidence, the risk to the individual, thus avoiding both the alarmism and the false idea that does not deserve your attention.
References
The U. S. Food and Drug Administration (FDA). Mounjaro® — Prescribing-Information. Warning: Risk of Thyroid C-Cell Tumors. A review of 2026.
Kamrul-Hasan ABM, et al. Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis. Endocrinology and Metabolism. 2025.
Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2026.
The brazilian National agency of Sanitary Surveillance (Anvisa). Mounjaro® (tirzepatida): to record and display for the control of chronic weight.
Content is up-to-date in September, 2026.
Read On To Find Out
Nausea, with tirzepatida: is it normal?
Tirzepatida the cause of indigestion? To understand the onset of discomfort after eating
Tirzepatida gives you diarrhea? Find out why it happens and what to do
